Compound GLP-1 medications: what the evidence actually says

What did @saltyaf22 actually say?

Honestly? Not much that can be fact-checked in the traditional sense. The transcript is almost entirely song lyrics, apparently from a motivational track playing over her video. The caption does the heavier lifting here: she mentions transitioning from a brand-name GLP-1 to a "compound GLP-1 medication," says she hasn't "felt this good in a very long time," and describes newfound energy as a "blessing." That's the substance we're working with.

To be fair to @saltyaf22, she's sharing a personal experience, not making clinical claims. She's not telling her 54,500 viewers that compound semaglutide is equivalent to Ozempic, or that GLP-1 drugs cure anything. She's saying she feels good. That matters, because it's a narrower claim than what we often see in this space, and we should evaluate it accordingly.

Does the science back this up?

The part about feeling better on a GLP-1 medication? There's actually solid data behind that kind of subjective improvement, even if her experience is anecdotal. The part about compounded GLP-1 drugs being a seamless substitute for brand-name versions is where the science gets murky, and that's the implicit claim embedded in her caption.

Multiple randomized controlled trials show GLP-1 receptor agonists improve quality of life measures beyond weight loss. Wilding et al. (2021, NEJM) found semaglutide produced significant improvements in physical function and general health scores compared to placebo. Jastreboff et al. (2022, NEJM) showed similar results for tirzepatide. Feeling more energetic, more engaged with daily life, less burdened by hunger, these are documented effects, not placebo fiction. So her claim of feeling "this good" tracks with what participants in clinical trials report.

The compound medication angle is where we hit a wall. Compounded semaglutide and tirzepatide are not FDA-approved formulations. The FDA has explicitly stated that compounded drugs are not reviewed for safety, efficacy, or manufacturing quality on the same basis as branded versions. That doesn't make them automatically dangerous, but it does mean the clinical trial data from Novo Nordisk and Eli Lilly trials does not automatically transfer to compounded versions.

What did they get wrong (or right)?

She got the lived experience part right, at least in the sense that it's consistent with documented outcomes. People on GLP-1 medications frequently report energy improvements, reduced food noise, and better engagement with daily activities. The phrase "I have not felt this good in a very long time" is exactly what clinical trial patient-reported outcome data reflects.

What's missing from her framing, and this is a real gap, is any acknowledgment that switching from a brand-name GLP-1 to a compounded version introduces meaningful variables. Compounded GLP-1 preparations vary in concentration, excipients, and manufacturing standards between pharmacies. The FDA has issued multiple warnings about compounded semaglutide products, including concerns about dosing accuracy and contamination. The American Society of Health-System Pharmacists has raised similar flags.

She doesn't claim compound equals brand, but by framing the transition as part of a seamless journey without caveat, the implicit message to viewers is that the switch carries no significant risk. That's not accurate. It's not catastrophically wrong either, because many people do access compounded GLP-1 medications without immediate adverse events. But the absence of acute harm is not the same as demonstrated equivalency.

What should you actually know?

If you're considering a compounded GLP-1 medication, either because brand-name versions are out of reach financially or because of ongoing shortages, there are specific things worth knowing before you act on the enthusiasm in videos like this one.

• Compounded semaglutide is not the same product as Wegovy or Ozempic. The FDA has been clear on this point, and "compounded" does not mean "identical but cheaper."
• The shortage status of semaglutide has changed. The FDA removed semaglutide from its drug shortage list in early 2024, which has legal implications for compounding pharmacies that were operating under shortage exemptions. Check current FDA guidance before assuming compounded versions are still being produced legally in your state.
• Quality varies significantly between compounding pharmacies. 503A pharmacies compound for individual patients with a prescription. 503B outsourcing facilities have stricter FDA oversight. These are not equivalent, and the distinction matters for safety.
• Feeling better quickly on a GLP-1 is real and documented. But feeling better is not a substitute for confirmed dosing accuracy, especially with tirzepatide, where dosing precision affects both efficacy and side effect profile.
• If a telehealth platform is prescribing compounded GLP-1 medications, ask specifically which pharmacy is filling the script and what their regulatory classification is. You have a right to that information.